EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application nebivolol tablets, 2.5mg, 5mg, 10mg, and 20mg. Aurobindo Pharma’s nebivolol tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic Tablets, of Allergan Sales.

Nebivolol tablets are indicated for the treatment of hypertension.

Nebivolol tablets has an estimated market size of US $978 Million for the twelve months ending October 2021, as per IQVIA.